Shield Therapeutics PLC US Composition of Matter Patent Allowed (9084P)
September 06 2017 - 1:00AM
UK Regulatory
TIDMSTX
RNS Number : 9084P
Shield Therapeutics PLC
06 September 2017
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION
Shield Therapeutics plc
("Shield" or the "Group")
US Composition of Matter Patent
International IP estate further strengthened for Feraccru(R)
London, UK, 6 September 2017: Shield Therapeutics plc (LSE:STX),
a specialty pharmaceutical company focused on secondary care, is
pleased to announce that the United States Patent and Trademark
Office (USPTO) has allowed a composition of matter patent
protecting the active substance of Feraccru(R), the Group's lead
European marketed product for the treatment of iron deficiency
anaemia (IDA), until late 2035 in the US.
This US patent application entitled "Crystalline Forms of Ferric
Maltol", was allowed after an expedited examination under the
Global Patent Prosecution Highway program (GPPH) based on the UK
patent (UK Patent No. GB2531742) "Polymorphs of Ferric Maltol",
which was granted in October 2016 and protects the active substance
of Feraccru through to late 2034 in the UK. In addition, during
2017 equivalent composition of matter patents for Feraccru were
granted until 2035 in Australia, Canada and Singapore.
Carl Sterritt, Founder and Chief Executive Officer of Shield
Therapeutics, commented: "This allowance from the US patent office
- being a further result of our continuing investment in
developing, strengthening and expanding Feraccru's intellectual
property - represents an important milestone for Shield. With
Feraccru now protected at the composition of matter level,
effectively providing market exclusivity through to 2035 in the
world's two largest and most important pharmaceutical regions (EU
& US) and beyond, and with additional key clinical data on the
near-term horizon, we find ourselves in a strong position from
which to exploit the significant commercial potential of
Feraccru."
- Ends -
For further information please contact:
Shield Therapeutics plc +44 (0)207 186 8500
Karl Keegan, Director of Corporate Development
Nominated Advisor and Joint Broker +44 (0)203 100 2222
Liberum Capital Limited
Christopher Britton/Steve Pearce
Joint Broker +44 (0)207 418 8900
Peel Hunt LLP
James Steel/Dr Christopher Golden
Financial PR Advisor +44 (0)203 709 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Philippa Gardner
US Investor Relations
Lazar Partners +1 (212) 867 1762
Fern Lazar/ David Carey
Market Abuse Regulation
This announcement is released by Shield Therapeutics plc and
contains inside information for the purposes of the Market Abuse
Regulation (EU) 596/2014 ("MAR") and is disclosed in accordance
with the Company's obligations under Article 17 of MAR. The person
who arranged for the release of this announcement on behalf of
Shield Therapeutics plc was Carl Sterritt, Chief Executive
Officer.
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company
focused on the commercialisation and development of late-stage,
hospital-focused pharmaceuticals which address areas of unmet
medical need. Our clear purpose is to help our patients become
people again, by enabling them to enjoy the things that make the
difference in their everyday lives. The Group has a marketed
product, Feraccru, for the treatment of iron deficiency anaemia
(IDA) in adult patients with inflammatory bowel disease (IBD) which
has exclusive IP rights until the mid-2030's. Shield Therapeutics,
headquartered in London, is listed on LSE's AIM under the ticker
STX. For more information please visit
www.shieldtherapeutics.com.
About Feraccru(R)
Feraccru is Shield's lead product and is a novel therapy for the
treatment of IDA. Feraccru received marketing authorisation across
Europe in February 2016 for the treatment of IDA in adult patients
with IBD and is in the early stages of commercialisation in
European markets. The Group is currently completing a pivotal Phase
3 clinical trial of Feraccru in IDA patients with pre-dialysis CKD
and expects to announce results of this study around the turn of
the year. A positive result is expected to facilitate the filing of
an NDA for Feraccru in the US as well as significantly broader
commercialisation in Europe and beyond.
This information is provided by RNS
The company news service from the London Stock Exchange
END
UPDUGUMABUPMGBA
(END) Dow Jones Newswires
September 06, 2017 02:00 ET (06:00 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024